BioSpace News Archive

In dire present times, with the threat of COVID-19 looming over, automated immunoassay analyzers market, one of the many sub-spheres of the global healthcare space, has been gaining a lot of prominence. Immunoassay analyzers generally use antibodies as reagents to identify the number of certain substances in a sample – this is particularly why they have been garnering a lot of traction during the COVID-19 phase.

The ablation devices market growth will be driven by growing preference for minimally invasive procedures. The rising occurrence of cancer and cardiovascular disorders globally will further fuel this growth.

Neuromod Devices Ltd, the Irish medical technology company specialising in non-invasive neuromodulation technologies, has announced the appointment of Dr. Jakob Kümmel as its Clinical Affairs Manager.

Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply agreement. The companies will work together to incorporate SITES Medical’s proprietary OsteoSync Ti Technology into future Conformis’ cementless total knee replacement products. “We are excited to be part

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases . The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT ® ) as a treatment consideration to further lower ather

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.

Dermata Therapeutics, LLC, a privately held biotechnology company focused on advanced treatments in medical and aesthetic dermatology, announced today that results from its Phase 2b study of DMT310 for the treatment of moderate to severe acne have been accepted as a poster presentation at the 2021 Maui Derm for Dermatologists Annual Conference,

Proven physician leader to assume a wide range of governance and leadership responsibilities on behalf of 8 Permanente Medical Groups

CairnSurgical, Inc., an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.